BMS-933043，一种用于治疗与精神分裂症相关认知缺陷的选择性α7烟碱型乙酰胆碱受体部分激动剂。
BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia.
作者信息
King Dalton, Iwuagwu Christiana, Cook Jim, McDonald Ivar M, Mate Robert, Zusi F Christopher, Hill Matthew D, Fang Haiquan, Zhao Rulin, Wang Bei, Easton Amy E, Miller Regina, Post-Munson Debra, Knox Ronald J, Gallagher Lizbeth, Westphal Ryan, Molski Thaddeus, Fan Jingsong, Clarke Wendy, Benitex Yulia, Lentz Kimberley A, Denton Rex, Morgan Daniel, Zaczek Robert, Lodge Nicholas J, Bristow Linda J, Macor John E, Olson Richard E
机构信息
Research and Development, Bristol-Myers Squibb , 5 Research Parkway, Wallingford, Connecticut 06492, United States.
出版信息
ACS Med Chem Lett. 2017 Feb 8;8(3):366-371. doi: 10.1021/acsmedchemlett.7b00032. eCollection 2017 Mar 9.
Abstract
The therapeutic treatment of negative symptoms and cognitive dysfunction associated with schizophrenia is a significant unmet medical need. Preclinical literature indicates that α7 neuronal nicotinic acetylcholine (nACh) receptor agonists may provide an effective approach to treating cognitive dysfunction in schizophrenia. We report herein the discovery and evaluation of (BMS-933043), a novel and potent α7 nACh receptor partial agonist with high selectivity against other nicotinic acetylcholine receptor subtypes (>100-fold) and the 5-HT receptor (>300-fold). activity was demonstrated in a preclinical model of cognitive impairment, mouse novel object recognition. BMS-933043 has completed Phase I clinical trials.
摘要
精神分裂症相关阴性症状和认知功能障碍的治疗是一项重大未满足医疗需求。临床前文献表明，α7神经元烟碱型乙酰胆碱（nACh）受体激动剂可能为治疗精神分裂症认知功能障碍提供有效方法。我们在此报告（BMS-933043）的发现与评估，它是一种新型强效α7 nACh受体部分激动剂，对其他烟碱型乙酰胆碱受体亚型（>100倍）和5-羟色胺受体（>300倍）具有高选择性。在认知障碍的临床前模型小鼠新物体识别实验中证明了其活性。BMS-933043已完成I期临床试验。
相似文献
1
BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia.BMS-933043，一种用于治疗与精神分裂症相关认知缺陷的选择性α7烟碱型乙酰胆碱受体部分激动剂。
ACS Med Chem Lett. 2017 Feb 8;8(3):366-371. doi: 10.1021/acsmedchemlett.7b00032. eCollection 2017 Mar 9.
2
The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia.新型烟碱型α7受体部分激动剂BMS-933043可改善精神分裂症临床前模型中的认知和感觉处理能力。
PLoS One. 2016 Jul 28;11(7):e0159996. doi: 10.1371/journal.pone.0159996. eCollection 2016.
3
Development of spiroguanidine-derived α7 neuronal nicotinic receptor partial agonists.螺胍衍生的α7神经元烟碱受体部分激动剂的开发。
Bioorg Med Chem Lett. 2017 Feb 1;27(3):578-581. doi: 10.1016/j.bmcl.2016.12.014. Epub 2016 Dec 7.
4
Effects of BMS-902483, an α7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents.BMS-902483（一种α7 烟碱型乙酰胆碱受体部分激动剂）对啮齿动物认知和感觉门控的影响及其与受体占有率的关系。
Eur J Pharmacol. 2017 Jul 15;807:1-11. doi: 10.1016/j.ejphar.2017.04.024. Epub 2017 Apr 22.
5
Procognitive effects of varenicline in the animal model of schizophrenia depend on α4β2- and α 7-nicotinic acetylcholine receptors.在精神分裂症动物模型中，伐伦克林的前认知效应取决于 α4β2-和 α 7-烟碱型乙酰胆碱受体。
J Psychopharmacol. 2018 Dec 3;33(1):269881118812097. doi: 10.1177/0269881118812097.
6
Advances in the discovery of novel positive allosteric modulators of the alpha7 nicotinic acetylcholine receptor.α7烟碱型乙酰胆碱受体新型正变构调节剂的发现进展
Recent Pat CNS Drug Discov. 2007 Jun;2(2):99-106. doi: 10.2174/157488907780832751.
7
The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.α7 烟碱型乙酰胆碱受体（α7 nAChR）激动剂治疗精神分裂症相关认知障碍的治疗潜力。
CNS Drugs. 2015 Jul;29(7):529-42. doi: 10.1007/s40263-015-0260-0.
8
Stimulation of nicotinic acetylcholine alpha7 receptors rescue schizophrenia-like cognitive impairments in rats.刺激烟碱型乙酰胆碱α7受体可挽救大鼠的精神分裂症样认知障碍。
J Psychopharmacol. 2017 Feb;31(2):260-271. doi: 10.1177/0269881116675509. Epub 2016 Nov 15.
9
Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats.α7烟碱型乙酰胆碱受体的正向变构调节剂可逆转氯胺酮诱导的大鼠精神分裂症样缺陷。
Neuropharmacology. 2016 Feb;101:389-400. doi: 10.1016/j.neuropharm.2015.07.034. Epub 2015 Jul 29.
10
Selective activation of α7 nicotinic acetylcholine receptors augments hippocampal oscillations.α7烟碱型乙酰胆碱受体的选择性激活增强海马体振荡。
Neuropharmacology. 2016 Nov;110(Pt A):102-108. doi: 10.1016/j.neuropharm.2016.07.010. Epub 2016 Jul 12.
引用本文的文献
1
Strategies for Treatment of Disease-Associated Dementia Beyond Alzheimer's Disease: An Update.治疗非阿尔茨海默病相关痴呆的策略：最新进展。
Curr Neuropharmacol. 2023;21(2):309-339. doi: 10.2174/1570159X20666220411083922.
2
Therapeutic Targeting of 7 Nicotinic Acetylcholine Receptors.治疗性靶向 7 型烟碱型乙酰胆碱受体
Pharmacol Rev. 2021 Jul;73(3):1118-1149. doi: 10.1124/pharmrev.120.000097.
3
Schizophrenia: synthetic strategies and recent advances in drug design.精神分裂症：药物设计中的合成策略与最新进展
Medchemcomm. 2018 Mar 16;9(5):759-782. doi: 10.1039/c7md00448f. eCollection 2018 May 1.
4
Nicotinic alpha 7 receptor agonists EVP-6124 and BMS-933043, attenuate scopolamine-induced deficits in visuo-spatial paired associates learning.烟碱型α7受体激动剂EVP - 6124和BMS - 933043可减轻东莨菪碱诱导的视觉空间配对联想学习缺陷。
PLoS One. 2017 Dec 19;12(12):e0187609. doi: 10.1371/journal.pone.0187609. eCollection 2017.
本文引用的文献
1
Design and synthesis of a novel series of 4-heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes as α7 nicotinic receptor agonists 2. Development of 4-heteroaryl SAR.新型系列4-杂芳基氨基-1'-氮杂螺[恶唑-5,3'-双环[2.2.2]辛烷]作为α7烟碱受体激动剂的设计与合成2. 4-杂芳基构效关系的研究
Bioorg Med Chem Lett. 2017 Mar 1;27(5):1261-1266. doi: 10.1016/j.bmcl.2017.01.058. Epub 2017 Jan 20.
2
Development of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes] as α7 Nicotinic Receptor Agonists.4-杂芳基氨基-1'-氮杂螺[恶唑-5,3'-双环[2.2.2]辛烷]作为α7烟碱受体激动剂的研发
ACS Med Chem Lett. 2016 Dec 1;8(1):133-137. doi: 10.1021/acsmedchemlett.6b00471. eCollection 2017 Jan 12.
3
Design and Synthesis of a New Series of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes as α7 Nicotinic Receptor Agonists. 1. Development of Pharmacophore and Early Structure-Activity Relationship.新型4-杂芳基氨基-1'-氮杂螺[恶唑-5,3'-双环[2.2.2]辛烷]系列作为α7烟碱型受体激动剂的设计与合成。1.药效团的开发及早期构效关系
J Med Chem. 2016 Dec 22;59(24):11171-11181. doi: 10.1021/acs.jmedchem.6b01506. Epub 2016 Dec 13.
4
The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia.新型烟碱型α7受体部分激动剂BMS-933043可改善精神分裂症临床前模型中的认知和感觉处理能力。
PLoS One. 2016 Jul 28;11(7):e0159996. doi: 10.1371/journal.pone.0159996. eCollection 2016.
5
Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.选择性α7烟碱受体部分激动剂恩西尼林在单次递增剂量及生物利用度研究中的药效学、药代动力学、安全性及耐受性
Clin Ther. 2015 Feb 1;37(2):311-24. doi: 10.1016/j.clinthera.2014.09.013. Epub 2014 Oct 14.
6
Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia.评估α-7 烟碱型乙酰胆碱受体在精神分裂症病理生理学和治疗中的作用。
Biochem Pharmacol. 2013 Oct 15;86(8):1122-32. doi: 10.1016/j.bcp.2013.06.031. Epub 2013 Jul 12.
7
A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.一项关于 α-7 烟碱型乙酰胆碱受体激动剂（TC-5619）治疗精神分裂症认知障碍的随机探索性试验。
Neuropsychopharmacology. 2013 May;38(6):968-75. doi: 10.1038/npp.2012.259. Epub 2012 Dec 18.
8
Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia.α7 型神经元烟碱型乙酰胆碱受体在精神分裂症中的药物靶点作用
Expert Opin Ther Targets. 2013 Feb;17(2):139-55. doi: 10.1517/14728222.2013.736498. Epub 2012 Dec 11.
9
Discovery of (2S,3R)-N-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]benzo[b]furan-2-carboxamide (TC-5619), a selective α7 nicotinic acetylcholine receptor agonist, for the treatment of cognitive disorders.（2S,3R）-N-[2-（吡啶-3-基甲基）-1-氮杂双环[2.2.2]辛-3-基]苯并[b]呋喃-2-甲酰胺（TC-5619）的发现，一种选择性α7 烟碱型乙酰胆碱受体激动剂，用于治疗认知障碍。
J Med Chem. 2012 Nov 26;55(22):9793-809. doi: 10.1021/jm301048a. Epub 2012 Nov 13.
10
EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors.EVP-6124 是一种新型、选择性 α7 烟碱型乙酰胆碱受体部分激动剂，通过增强 α7 烟碱型乙酰胆碱受体对乙酰胆碱的反应来改善记忆表现。
Neuropharmacology. 2012 Feb;62(2):1099-110. doi: 10.1016/j.neuropharm.2011.10.024. Epub 2011 Nov 10.
Zotero 插件